CN102038958A - 一种纳米粒子组合物及其应用 - Google Patents
一种纳米粒子组合物及其应用 Download PDFInfo
- Publication number
- CN102038958A CN102038958A CN2009101106341A CN200910110634A CN102038958A CN 102038958 A CN102038958 A CN 102038958A CN 2009101106341 A CN2009101106341 A CN 2009101106341A CN 200910110634 A CN200910110634 A CN 200910110634A CN 102038958 A CN102038958 A CN 102038958A
- Authority
- CN
- China
- Prior art keywords
- plasmid
- nanoparticle compositions
- polymine
- cell
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims description 50
- 239000013612 plasmid Substances 0.000 claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229960000304 folic acid Drugs 0.000 claims abstract description 14
- 239000011724 folic acid Substances 0.000 claims abstract description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 30
- 102000000588 Interleukin-2 Human genes 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 9
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract description 5
- 102000055277 human IL2 Human genes 0.000 abstract description 3
- 230000003405 preventing effect Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 29
- 239000007924 injection Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 201000001441 melanoma Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 210000000822 natural killer cell Anatomy 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102000006992 Interferon-alpha Human genes 0.000 description 10
- 108010047761 Interferon-alpha Proteins 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 101150014702 hil-2 gene Proteins 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910110634.1A CN102038958B (zh) | 2009-10-19 | 2009-10-19 | 一种纳米粒子组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910110634.1A CN102038958B (zh) | 2009-10-19 | 2009-10-19 | 一种纳米粒子组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102038958A true CN102038958A (zh) | 2011-05-04 |
CN102038958B CN102038958B (zh) | 2015-08-12 |
Family
ID=43905716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910110634.1A Expired - Fee Related CN102038958B (zh) | 2009-10-19 | 2009-10-19 | 一种纳米粒子组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102038958B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412943A (zh) * | 2015-09-25 | 2016-03-23 | 徐州医学院 | 一种纳米粒子组合物及其抗肿瘤应用 |
CN105435243A (zh) * | 2015-09-25 | 2016-03-30 | 徐州医学院 | 一种纳米粒子基因组合药物及其应用 |
CN105457040A (zh) * | 2015-09-25 | 2016-04-06 | 徐州医学院 | 一种纳米粒子组合物及其在抗肿瘤血管生成中的应用 |
CN107929754A (zh) * | 2018-01-12 | 2018-04-20 | 昆明医科大学 | 一种多聚阳离子载体包被重组腺病毒在制备抗肿瘤基因药物中的应用 |
CN114099639A (zh) * | 2021-11-25 | 2022-03-01 | 徐州医科大学 | H1-pHSP65纳米疫苗及其制备方法和用途 |
-
2009
- 2009-10-19 CN CN200910110634.1A patent/CN102038958B/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412943A (zh) * | 2015-09-25 | 2016-03-23 | 徐州医学院 | 一种纳米粒子组合物及其抗肿瘤应用 |
CN105435243A (zh) * | 2015-09-25 | 2016-03-30 | 徐州医学院 | 一种纳米粒子基因组合药物及其应用 |
CN105457040A (zh) * | 2015-09-25 | 2016-04-06 | 徐州医学院 | 一种纳米粒子组合物及其在抗肿瘤血管生成中的应用 |
CN107929754A (zh) * | 2018-01-12 | 2018-04-20 | 昆明医科大学 | 一种多聚阳离子载体包被重组腺病毒在制备抗肿瘤基因药物中的应用 |
CN114099639A (zh) * | 2021-11-25 | 2022-03-01 | 徐州医科大学 | H1-pHSP65纳米疫苗及其制备方法和用途 |
CN114099639B (zh) * | 2021-11-25 | 2024-03-01 | 徐州医科大学 | H1-pHSP65纳米疫苗及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102038958B (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ren et al. | Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a phase I/II clinical protocol | |
CN101111154B (zh) | 联合免疫基因疗法和化学疗法用于治疗癌症和过度增生性疾病 | |
Assi et al. | Gene therapy for brain tumors: basic developments and clinical implementation | |
Li et al. | Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy | |
CN107074967A (zh) | 白介素‑2/白介素‑2受体α融合蛋白和使用方法 | |
Tamura et al. | Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer | |
CN102038958B (zh) | 一种纳米粒子组合物及其应用 | |
JP7066669B2 (ja) | 炎症性関節疾患の治療方法 | |
Mendiratta et al. | Combination of interleukin 12 and interferon α gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma | |
CN112826808B (zh) | 一种环二核苷酸或其类似物的中性/阳离子混合脂材纳米制剂及其应用 | |
Ohe et al. | Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells | |
CN113318224B (zh) | 双轮状纳米颗粒及其制备方法 | |
Horinaga et al. | Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model | |
CN106520778A (zh) | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 | |
Goto et al. | Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo | |
US20070111959A1 (en) | Combination gene for use in inhibiting cancerous cell growth | |
Li et al. | Administration route-and immune cell activation-dependent tumor eradication by IL12 electrotransfer | |
WO2006032525A2 (en) | Combinational therapy for treating cancer | |
Shao et al. | KERS‐Inspired Nanostructured Mineral Coatings Boost IFN‐γ mRNA Therapeutic Index for Antitumor Immunotherapy | |
Egilmez et al. | Controlled-release particulate cytokine adjuvants for cancer therapy | |
CN101804209B (zh) | Pedf基因plga纳米复合物及其制备方法和用途 | |
Lan et al. | Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells 2021, 10, 100 | |
CN115702940A (zh) | 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用 | |
Butowski | Immunostimulants for malignant gliomas | |
Zhu et al. | Interleukin-12: Structure, Function, and Its Impact in Colorectal Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Hong Document name: Decision of Rejection |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Hong Document name: Notification of an Office Action |
|
DD01 | Delivery of document by public notice |
Addressee: Yao Hong Document name: Notification that Application Deemed to be Withdrawn |
|
DD01 | Delivery of document by public notice |
Addressee: Zhang Wenbo Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 Termination date: 20181019 |